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Abstract  Imaging-guided  percutaneous  biopsies  in  patients  in  oncology  provide  an  accurate
diagnosis  of  malignant  tumors.  Percutaneous  biopsy  results  are  improved  by  correct  use  of  samp-
ling procedures.  The  risks  of  percutaneous  biopsy  are  low  and  its  complications  are  generally
moderate.  These  risks  can  be  reduced  using  aids  such  as  blund  tip  introducers,  hydrodissection
and correct  patient  positioning.  The  multidisciplinary  team  meetings  dialogue  between  oncolo-Optimization gist, surgeon  and  radiologist  correctly  deﬁnes  the  indications  in  order  to  improve  the  treatment
strategies.
© 2014  Published  by  Elsevier  Masson  SAS  on  behalf  of  the  Éditions  françaises  de  radiologie.
Percutaneous  needle  biopsies  (cytology  aspirates  and  core  needle  biopsies)  are  safe  with
high  performance  and  can  be  used  to  diagnose  cancer,  benign  process  or  infection  in
patients  in  oncology  [1—13]. They  are  less  invasive  alternatives  to  surgical  biopsy,  reduc-
ing  morbidity  and  mortality  and  should  be  considered  as  the  ﬁrst  stage  in  diagnosis  before
surgery.  The  efﬁcacy  and  safety  results  of  percutaneous  needle  biopsies  (PNB)  depend  on
the  choice  of  indication,  technique  and  patient  monitoring.  PNB  include  cytology  aspiration
and  microbiopsy.  Cytology  aspiration  is  performed  with  a  hollow  needle  (22  G  or  smaller)
and  enables  cells  to  be  aspirated  for  cytological  examination.  Microbiopsy  is  performed
using  a  less  ﬁne  needle  (20  G  or  greater)  equipped  with  a  mechanism  which  can  cut  a  core
of  tissue  for  histological  analysis.  Superﬁcial  procedures  are  distinguished  from  deep  ones
because  of  the  high  risk  of  complications  in  the  deep  procedures  (bleeding,  accidental
puncture  of  bowel,  blood  vessels.  .  .):
• superﬁcial  procedures:  biopsies  of  thyroid,  cervical,  supraclavicular  and  axillary  lymphnodes,  subcutaneous  and  muscle  limb  lesions;
• deep  procedures:  chest  biopsies  (lung  and  mediastinal),  abdominal  (liver,  kidneys,
adenopathies)  and  pelvic  (adenopathies)  biopsies.
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malignant)  and  the  technique  (number  of  samples,  needle48  
ndications
he  success  of  PNB  is  closely  linked  to  the  choice  of  indi-
ation.  A  literature  review  shows  that  95%  of  indications
or  PNB  in  expert  centers  belong  to  one  of  the  following
 categories  [14]:
the  differential  diagnosis  of  a  lesion  as  being  benign  or
malignant  (Fig.  1);
obtaining  material  for  microbiological  analysis  in  sus-
pected  infection;
staging  assessment  of  a  patient  being  treated  for  a malig-
nant  tumor  with  suspected  metastatic  extension;
assessment  of  the  type  and  extension  of  diffuse  parenchy-
mal  lesions  (liver  cirrhosis,  renal  transplant  rejection,
glomerulopathy).
The  indications  not  mentioned  in  this  group  should  not
xceed  5%  of  the  total  imaging  percutaneous  puncture  activ-
ty  although  this  proportion  is  likely  to  rise  because  of
he  emergence  of  new  indications  such  as  investigating
or  potential  sites  of  action  for  new  targeted  treatments
for  example,  Herceptin  or  Mabthera).  The  investigation  is
sed  for  primary  tumors  and  metastases,  which  may  contain
utations  from  the  primary  lesion.  As  a  result  of  increased
urvival,  patients  are  now  sometimes  being  monitored  for
everal  cancers.  Samples  of  metastases  from  these  patients
re  essential  to  deﬁne  the  cancer  involve  and  tailor  treat-
ent  (Fig.  2).
igure 1. Incidental discovery of a 4 cm left renal mass in a routine r
 68-year-old male patient. The appearance of the renal mass suggests
he lesion allowing several samples (c) to be taken through the introdu
d, arrow), through the introducer at the end of the procedure to avoid 
d
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There  are  no  absolute  contraindications  to  percutaneous
iopsy.  On  the  other  hand  some  relative  contraindications
hould  be  understood  in  order  to  correct  these  where  possi-
le  before  the  procedure:
some  coagulopathies  which  cannot  be  corrected;
severe  heart  or  lung  failure  and  unstable  hemodynamics;
lack  of  a  safe  puncture  path;
patients  who  cannot  cooperate  or  be  positioned  correctly
for  the  procedure;
pregnancy,  if  the  guiding  method  uses  X-rays;
a  mass  suspected  to  be  a  sarcoma.  Multidisciplinary  team
meetings  (MDT)  now  allow  surgeons  and  radiologists  to
agree  about  the  biopsy  path  so  that  this  can  be  excised
at  the  same  time  as  the  tumor  (Fig.  3).  Knowledge  of  the
histological  type  of  sarcoma  allows  surgeon  to  optimize
the  surgical  procedure  (Fig.  4).
Percutaneous  biopsies  of  sarcomas,  however,  produce
etter  results  for  bone  sites  than  in  soft  tissues  [15].
uccess rate
he  success  rate  depends  on  several  factors  relating  to  the
arget  (site  and  size  of  the  lesion,  whether  it  is  benign  orenal artery ultrasound before starting antihypertensive therapy in
 renal cancer (a, arrowheads). Insertion of an introducer (b) into
cer. Injection of biological glue mixed with the contrast medium
post-puncture bleeding of hypervascularized lesions.
iameter).
The  literature  provides  indicators  about  the  success  of
NB  in  expert  centers,  allowing  interventional  radiologists
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Figure 2. Past history of breast and colonic cancer in a 54-year-old female patient. Two hypermetabolic lymphadenopathies found on
18FDG PET CT: one above the left clavicle (a arrowhead, SUV = 2.4 IU) and one left lumbo-aortic (b, arrow, SUV = 7 IU). Biopsies of the
supraclavicular lymphadenopathy under ultrasound guidance (d) and CT-guided biopsy of the lumbo-aortic lymphadenopathy (c) showed
recurrence of the colonic cancer in both sites.
Figure 3. Patient referred for biopsy of a soft tissue mass that developed on the anterior aspect of the top of his right thigh (a, arrowheads).
Four samples (b and c), obtained using a 14 G coaxial system were ﬁxed in AFA (n = 2) and frozen (n = 2). The pathologist found a liposarcoma.
In suspected sarcoma, the puncture tract which is visible because of introduction of air bullae (d, arrows) is marked in China ink in order
to enable the surgeon to remove it at the same time as the tumor.
650  C.  de  Bazelaire  et  al.
Figure 4. Patient referred for biopsy of a soft tissue mass which developed on the posterior aspect of his left thigh before surgery (a,
arrowheads). Four samples (b and c), obtained using a 14 G coaxial system were ﬁxed in AFA (n = 2) and frozen (n = 2). The pathologist found
a mantel cell lymphoma, surgery was cancelled and the patient was started on chemotherapy.
Table  1  Diagnostic  performance  of  percutaneous  needle  biopsies  (PNB)  (level  of  evidence  B).
Site  of  PNB  Average  reported
success  rate  (%)
Reported  success
rate  interval  (%)
Suggested
threshold  (%)
Chest  and  lung  (14—22) 77—96  89  75
Muscle  and  skeleton  (23—30) 76—93 82  70
Other  sites  (31—36) 70—90 89  75
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o  assess  their  own  performance  and  do  what  is  necessary
o  keep  within  these  standards  (Tables  1  and  2)  [14].
Functional  imaging  is  a  new  tool  that  improves  the
iagnostic  return  of  biopsies  and  assists  the  radiologist  in
hoosing  the  best  target.  PET  CT  can  be  used  to  select  the
esions  or  parts  of  tumors  that  take  up  most 18FDG  (Fig.  5).
ike  PET  CT,  whole  body  diffusion  weighted  imaging  can
how  up  lesions  not  seen  with  other  imaging  methods  [16].
Table  2  Diagnostic  performance  of  percutaneous  nee-
dle  biopsies  (PNB)  (level  of  evidence  B).
Average  success
rate  (%)
Suggested
threshold  (%)
Total  (15)  94  90
Malignant  lesions  (37)  91  75
Fungal  infections  (38)  34  30
i
t
a
P
A
a
t
a
b
s85  75
inding  additional  lesions  can  allow  a more  accessible  tar-
et  to  be  chosen.  Diffusion  weighted  imaging  can  also  help
o  avoid  puncturing  consolidations  that  represent  ventila-
ory  disorders  around  lung  tumors  (Fig.  6)  [17].  Perfusion
eighted  imaging  can  be  used  to  target  lesions  where  signif-
cant  neoangiogenesis  is  present  and  elastography  improves
argeting  of  biopsies  by  visualizing  the  hardest  targets  or
reas  within  the  tumor  (Fig.  7).
re-procedure assessment
 hemostasis  proﬁle  is  recommended  before  the  biopsies
re  taken  [18]. This  depends  on  the  bleeding  risk,  due  of
he  site  of  the  biopsy  (superﬁcial  or  deep).  The  decision
s  to  whether  to  stop  anticoagulation  also  depends  on  the
leeding  risk  (Table  3).
An  intravenous  line  should  be  inserted  before  deep  biop-
ies  are  taken  (abdomen,  pelvis  or  mediastinum).
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Figure 5. Patient referred for biopsy of a right lower lobe lung mass (a, arrowheads). PET CT showed that only the anterior and lateral
portion of the lesion was hypermetabolic (a, arrow). The biopsy was therefore orientated towards this area (b, blue area, c and d) and
showed an adenocarcinoma.
Figure 6. Diffusion weighted MR (a) and high resolution chest CT (b) centered on focal alveolar consolidation in a patient being followed
up for abdominal large B cell lymphoma. Diffusion weighted MR showed restricted diffusion in the postero-external portion of the lesion
and that the internal portion represented atelectasis. The biopsy targeted in the external portion found pulmonary lymphoma.
652  C.  de  Bazelaire  et  al.
Figure 7. Female patient referred for biopsy of a mass in the supero-external quadrant of her left breast (a, arrowheads). Elastography
showed that the superﬁcial portion of the lesion was redder, i.e. harder than the deep part (b, arrow). The biopsy was therefore orientated
towards this area (c and d, arrow) and showed an inﬁltrating ductal carcinoma.
Table  3  Hemostasis  proﬁle  (level  of  evidence  B)  [18].
Procedures  Recommended  hemostasis  proﬁle
before  biopsy
Treatment
Low  risk
Cytology  aspirate  or  superﬁcial
biopsy
Thyroid
Superﬁcial  lymph  nodes
INR:  if  patient  on  vitamin  K
antagonist  or  being  monitored  for
hepatic  impairment
APTT:  if  heparin  treatment
Platelet  count:  not  recommended
Hematocrit:  not  recommended
INR:  correct  if  >  2.0
Plavix®:  do  not  stop
Aspirin:  do  not  stop
LMWH  (effective  dose):  omit  one  dose
immediately  before  the  procedure
Moderate  risk
Biopsy  of  INR:  correct  if  >  1,5
Chest  wall
Lung
Intra-abdominal
Retroperitoneal
Hepatic
INR:  recommended
APTT:  recommended  in  patients
receiving  LMWH
Platelet  count:  not  recommended
Hematocrit:  not  recommended
TCA:  correct  if  >  1,5
Platelet  transfusion  if  <  50,000
Hematocrit:  no  threshold  for  transfusion
Plavix®:  stop  5  days  before  the  procedure
Aspirin:  do  not  stop
LMWH:  omit  a  dose  immediately  before
the  procedure
High  risk
Renal  biopsy  INR:  recommended
APTT:  recommended  in  patients
receiving  LMWH
Platelet  count:  recommended
Hematocrit:  recommended
INR:  correct  if  >  1,5
TCA:  correct  if  >  1,5
Platelet  transfusion  if  <  50,000
Hematocrit:  no  threshold  for  transfusion
Plavix®:  stop  5  days  before  the  procedure
Aspirin:  stop  5  days  before  the  procedure
LMWH:  stop  24  h  before  the  procedure
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•Figure 8. Biopsy of an infra-carenal mass (a, arrowheads). Ther
aorta red area). Placing the patient in the lateral decubitus positio
the esophagus (which moved with the rest of the mediastinum) and
No  assessment  is  required  for  cytology  aspirates  as  the
ﬁne  needles  (22  G  or  24  G)  used  do  not  cause  any  complica-
tion  if  a  blood  vessel  or  the  bowel  is  punctured  accidentally.
Clear  explanations  about  the  purposes,  stages  and  risks
of  the  procedure  should  be  given  to  the  patient.
Biopsy materials and approach routes
The  area  to  be  biopsied  should  be  cleaned  and  protected  by
a  sterile  surgical  drape  with  an  access  opening  in  it.
No  anesthesia  is  required  for  cytology  aspirates.  The
biopsy  path  is  anesthetized  with  an  injection  of  Xylocaïne®
for  biopsies  (maximum  20  mL).
Cytology  aspirates  are  taken  with  a  ﬁne  needle  (22  G  or
24  G).
At least  two  samples  are  recommended  for  biopsies.  The
use  of  a  coaxial  system  with  an  introducer  also  reduces  the
risk  of  possible  accidental  punctures,  pain  or  dissemination
when  the  biopsy  gun  is  used  repeatedly.
The  procedure  may  be  hindered  when  they  are  inserting
the  introducer  if  blood  vessels,  ureters,  bowel  or  a  solid
organ  lie  between  the  skin  puncture  site  and  the  target.
Correct  patient  positioning  can  often  facilitate  the  biopsy
process  by  moving  these  structures  away  from  the  path  of
the  needle  (Fig.  8).An  injection  of  physiological  saline  through  the  intro-
ducer  can  widen  the  path  or  displace  a  hazardous  structure
away  from  the  puncture  path.  A  soft  tipped  introducer  is  also
recommended  when  certain  hazardous  structures  remain
•o space between the esophagus and the aorta (b, beige area and
adened the space between the aorta (which remained ﬁxed) and
ided access to the lesion (c, d).
resent  along  the  needle  puncture  path  despite  all  efforts
Fig.  9).
The  soft  tipped  introducer  is  advanced  towards  the  tar-
et,  and  then  slides  over  these  structures  without  damaging
hem  (Fig.  10)  [19].
The  type  of  gun  depends  on  the  neighboring  environment
round  the  target.  Automatic  guns  are  useful  when  the  tar-
et  is  very  hard  (Hodgkin’s)  or  mobile  in  a  fatty  environment
breast  or  renal  mass).
Semi-automatic  guns  are  recommended  for  all  other
iopsies.  These  control  the  progression  of  the  sampling  win-
ow  in  the  target  and  avoid  a  hazardous  structure  outside
f  the  lesion  by  controlling  the  movement  of  the  needle.
The  caliber  of  the  gun  should  be  appropriate  for  the
iameter  of  the  target  and  the  risk  of  bleeding  from  the
arenchyma  it  passes  through:
liver  and  lung:  18  G,  kidney:  16  G,  fat  14  G;
diameter  of  the  target  <  10  mm:  18  G,  10  to  20  mm:
16  G,  >  20  mm:  14  G.
There  is  no  point  in  taking  more  than  4  samples  from  the
ame  target  although  it  is  essential  to  adapt  the  sampling
rocedures  for  the  possible  diagnoses:
dry  Steril  Tube:  bacterial,  fungal  or  viral  infection,  etc;
ﬁxation  in  AFA  or  formol  (morphological  and  par-
tial  immunohistochemical  analysis),  cancers,  lymphoma,
benign  tumors,  liver  ﬁbrosis,  nephropathy,  infections
(fungal  infections  or  tuberculosis);
freezing  in  liquid  nitrogen  (immunohistochemical  analy-
sis,  molecular  biology,  tumor  archive):  targeted  therapy
654  C.  de  Bazelaire  et  al.
Figure 9. Introducer system with hollow cannula, soft tipped sheath and pointed tipped sheath.
Figure 10. Biopsy of mesenteric adenopathy (a, arrowheads). The use of a soft tipped introducer enables it to pass into the mesenteric
fat sliding against the left colon, liver and stomach without damaging these structures (b and c). A check at the time of sampling conﬁrmed
the position of the sampling window with respect to the target, mesenteric vessels and portal trunk (d).
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agno
sia, f
hFigure 11. Sampling procedures should be appropriate for the di
in all situations, freezing for suspected solid cancer or blood dyscra
and slide smears for rapid diagnosis of a blood dyscrasia (2 hours).
for  breast  cancers,  lymphomas,  melanomas,  assessment
of  glomerulopathies;• slide  smears  for  rapid  diagnosis  (2  hours)  of  aggressive
malignant  blood  diseases  such  as  Burkitt’s  lymphoma
(Fig.  11)  [20].
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Table  4  Complication  rates  for  percutaneous  needle  biopsies
Serious  complications  
Non-transthoracic  or
mediastinal  PNB
Bleeding  requiring
transfusion  or  speciﬁc
treatment
Kid
l
18
s
18
Liv
Sp
Ot
Dissemination  along  the  puncture
Pneumothorax  with  drainage  
Transthoracic  or
mediastinal  PNB
Hemoptysis  requiring  hospitaliza
or  speciﬁc  treatment  (5,  77)
Pneumothorax  D
or  
SS  
D
(15
N
16
82
Air  embolism  (77,  89)  
Vaso-vagal  effect  (15)  ses hypothesis. There are three main types of procedures: ﬁxation
resh samples to investigate for bacterial, viral or fungal infections
The  interventional  radiologist  should  ensure  that  the
istology/biochemistry/bacteriology  reports  are  correctly
ddressed  to  the  doctor  who  requested  the  biopsy  and
hould  tell  the  patient  who  will  give  him/her  the
esults.
 (PNB)  (level  of  evidence  B)  [14].
Complication
rate  (%)
Suggested
threshold  (%)
ney  (9,  39-53)
arge  diameter  <
G
2.7—6.6  10
mall  diameter  >
G
0.5—2.8  5
er  (43,  54-62)  0.3—3.3  5
leen  (63-65)  0.0—8.3  10
hers  (33,  66)  0.1—3.0  6
 tract  (66-76)  0,0—3,4  5
0,5  1
tion 0,5  2
rainage  >  3  days
pleural  symphysis
(37,  78)
1—2  3
rainage  <  3  days
,  16,  37,  79-87)
2—15  20
ot  drained  (15,
,  37,  79,  80,
-88)
12—45  45
0.06—0.07  <  0.1
0.3  <  1
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• A hemostasis  proﬁle  is  recommended  before  biopsies
and  is  based  on  the  IN,  APTT,  and  platelet  count.
Interpretation  of  this  depends  on  the  risk  of  bleeding
due  to  the  site  of  the  biopsy  (superﬁcial  or  deep).  The
decision  to  stop  anticoagulants  also  depends  on  the
risk  of  bleeding  from  the  PNB  (kidneys,  lung,  liver
and  spleen).
• The  main  complications  are  bleeding,  infections,
perforation  and  accident  puncture  of  solid  organs.
Heavy  bleeding  is  rare  and  its  incidence  depends  on
the  diameter  of  the  puncture  needle,  the  mechanism
of  tissue  division,  vascularization  of  the  lesion  and
the  target  organ.  Infection  is  also  rare.  Accidental
puncture  of  a  dangerous  structure  requiring  speciﬁc
D
T
c
R
[
adrenal masses: evaluation of 50 adrenal biopsies. AJR Am J56  
omplications
he  main  complications  are  bleeding,  infection,  perforation
nd  accidental  puncture  of  solid  organs  [14].  Heavy  bleed-
ng  is  rare  and  its  incidence  depends  on  the  diameter  of  the
uncture  needle  tissue,  cutting  mechanism,  vascularization
f  the  lesion  and  the  target  organ  [21,22].  Infection  is  also
are.  Accidental  puncture  of  a  hazardous  structure  (pneu-
othorax,  bleeding,  bowel  perforation)  requiring  speciﬁc
reatment  should  not  occur  in  over  2%  of  PNB.  Hematuria,
lveolar  hemorrhage  and  post-PNB  hemoptysis  generally
equire  no  speciﬁc  treatment.  The  average  complication
ates  reported  in  the  literature  are  shown  in  Table  4  and
an  be  used  as  an  indicator  for  interventional  radiologists  to
enchmark  their  own  activities  [14].  There  are  no  indicators
or  very  rare  complications  (ﬂare  of  hypertension  from  punc-
ure  of  a  phechromocytoma,  acute  pancreatitis,  peritonitis
r  air  embolism)  (Table  4).
onitoring
ytology  aspirates  and  superﬁcial  biopsies  do  not  require
ny  monitoring  and  are  carried  out  on  an  ambulatory  basis.
f  bleeding  occurs,  local  compression  for  3—5  minutes  is  usu-
lly  sufﬁcient.
Liver  and  spleen  biopsies  require  hospital  admission  for
4  hours  to  identify  and  manage  bleeding  (with  emboliza-
ion).
Lung  biopsies  require  day  hospital  monitoring  for  6  hours
o  identify  and  manage  any  pneumothorax.
Renal  biopsies  require  monitoring  for  6  hours  to  identify
nd  manage  bleeding.
Deep  lymph  node  biopsies  require  monitoring  for  2  hours
o  identify  and  manage  bleeding.
onclusion
maging-guided,  percutaneous  biopsies  in  oncology  patients
rovide  a  very  accurate  diagnosis  of  malignant  tumors.
he  results  of  percutaneous  biopsies  are  improved  by
orrect  use  of  sampling  procedures.  The  risks  of  percu-
aneous  biopsy  are  low  and  complications  are  generally
ild.  These  risks  can  be  reduced  using  tricks  such  as  soft
ipped  introducers,  hydrodissection  and  correct  patient
ositioning.  The  MDT  dialogue  between  oncologist,  surgeon
nd  radiologist  correctly  deﬁnes  the  indications  to  improve
reatment  strategies.
TAKE-HOME  MESSAGES
• The  success  of  biopsies  is  closely  related  to
the  choice  of  indications.  Ninety-ﬁve  percent
of  indications  should  belong  to  one  of  the
following  4  categories  (apart  from  expert  centers):
differential  diagnosis  between  benign  and  malignant
disease,  suspected  infection,  suspected  metastatic
extension,  assessment  of  diffuse  parenchymal
lesions.
[treatment  should  not  occur  in  more  than  2%  of
biopsies.
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